MS and Demyelinating Disorders

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep and sleep disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 19, 2023.

The assistant professor of neurology at the University of North Carolina at Chapel Hill discussed the importance of recognizing disability as part of diversity in neurology, emphasizing the need for inclusive communication and accessibility for disabled patients. [WATCH TIME: 10 minutes]

Anand Patel, MD, CPI, chief medical officer at Conquest Research, discussed a phase 2 study that investigated the efficacy and safety of LX9211, an oral medication targeting neuropathic pain.

Neurological rehabilitation, or neurorehabilitation, can be described as the use of rehabilitation interventions to improve or maintain function and quality of life in the context of neurological conditions.

Bruce Hughes, MD, comments on the current use and access to biomarkers in MS management, as well as sharing how NfL is being used in clinical practice presently.

An expert neurologist discusses pNfL being utilized outside of clinical trials and implemented into clinical practice for the treatment of MS.

Bruce Hughes, MD, reviews clinical trials of use of NfL in MS, highlighting data on the Bruton’s tyrosine kinase inhibitor, evobrutinib.

Bruce Hughes, MD, provides an overview of the use of neurofilament light chain (NfL) as a biomarker in multiple sclerosis (MS), highlighting the accuracy and reliability of plasma/serum NfL (pNfL) and cerebrospinal fluid (CSF) NfL measurements.

Findings from the 12-week study showed a significant decrease in total number of new gadolinium-enhancing lesions in patients with relapsing MS on fenebrutinib relative to placebo.

Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, discuss a patient case with relapsing/remitting multiple sclerosis progression and share considerations for switching treatment.

Here's some of what is coming soon to NeurologyLive® this week.

Teri Schreiner, MD, associate professor at the University of Colorado, talked about the impact of B-cell-depleting therapy in pediatric patients with MS infected with COVID-19.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 12, 2023.

The strongest associations observed in the study were between microglial activation at the rim of chronic T1 hyperintense lesion and in the perilesional normal appearing white matter and serum neurofilament light.

Jeffrey Bennett, MD, PhD, professor of neurology and ophthalmology at the University of Colorado Denver talked about inebilizumab for patients with NMOSD from the N-MOmentum trial.

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided perspective on a phase 3 study of patients with NMOSD in which no relapses were recorded while on ravulizumab.

The director and chief research scientist at Tisch MS Research Center of New York talked about a phase 2 data study on stem cell treatment for multiple sclerosis that was presented at the 2023 AAN Annual Meeting. [WATCH TIME: 7 minutes]

The panel discusses access challenges faced by patients with multiple sclerosis.

The panel discusses the role of shared decision-making to improve treatment outcomes for patients living with multiple sclerosis.

The director of the Mellen Center for MS at Cleveland Clinic talked about the ENSEMBLE study results that were presented at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The assistant professor of neurology at Mayo Clinic spoke about understanding the phenotypes and epidemiology of autoimmune encephalitis at the 2023 AAN Annual Meeting. [WATCH TIME: 4 minutes]